Loading the next story…
Skip to content
NERVE.NEWS
TodayStoriesWinners & LosersForecasts
Auto
Set the atmosphere

Scenery follows the section you’re exploring.

Subscribe

Explore Nerve

Desks & tools

The briefingStory hubsForecastsPrimersLiveblogWinners & LosersSearchSaved storiesDataWires

Categories

All categories →PoliticsEconomyForeign AffairsDefense & SecurityImmigration & BorderMedia & TechCulture & SocietyLaw & JusticeEducationDaily RoundupNewsroom
Subscribe to Nerve
Higher contrast, reduced visual effects, and simplified popups. Your choice is saved for this browser.
TodayBriefingSaved
Back to the briefingBriefingNERVE.NEWS

The Nerve Briefing

Power, culture, technology, and the world taking shape — when we publish. Subscribe →

NERVE.NEWS

A clear view of a changing world. Reporting and ideas with an American perspective.

Coverage

  • Economy
  • Foreign Affairs
  • Politics
  • Media & Tech
  • Culture & Society
  • Opinion
  • All sections
  • Wires
  • Forecasts

Resources

  • Primers
  • Policy Papers
  • Newsletter
  • RSS — All articles
  • RSS — Wires
  • Data
  • The briefing

Publication

  • Subscribe
  • Winners & Losers
  • Editorial Policy
  • About
© 2026 Nerve News. All rights reserved.
EthicsPrivacyAbout
FDA Leadership Uncertainty Raises Concerns Over Agency Stability — Nerve Wires | Nerve News
Home/Wires
WireMay 11, 2026 at 11:02 AM

FDA Leadership Uncertainty Raises Concerns Over Agency Stability

2 min left
0%

Reading controls

Reading Progress0%
Time remaining2 min
Total reading time2 min
Focus modeDims surrounding paragraphs

Editorial note

Comments

Previous

U.S. and China Enter Talks on AI Governance Amid Rising Concerns

Next

Trump Meets Xi Jinping in China Amid Rising Trade and Geopolitical Tensions

The Food and Drug Administration (FDA), a cornerstone of U.S. health regulation, is experiencing significant turbulence under its current leadership. Reports suggesting the possible ousting of Commissioner Marty Makary have heightened concerns over the agency's stability and its ability to regulate effectively. The FDA oversees approximately one-fifth of the U.S. economy, meaning any disarray can have widespread economic and health implications.

Current State of Affairs

Speculation about Makary's departure began circulating last week, with multiple outlets reporting that President Trump had authorized his firing. However, the White House has remained ambiguous, offering no clear confirmation of Makary's status. Amidst this uncertainty, Makary continues to push forward with initiatives aimed at accelerating drug approvals and reducing regulatory burdens, elements that could significantly impact the industry regardless of his tenure.

The Implications of Leadership Change

If Makary exits, potential replacements from within the FDA include Kyle Diamantas, Deputy Commissioner for Food. There is also speculation about the return of former FDA Commissioner Stephen Hahn or Brett Giroir. Analysts predict a shift toward a more pro-industry, predictable leadership, given recent trends.

We expect the White House to nominate a less disruptive, pro-industry commissioner, consistent with other recent steps the administration has taken to moderate the agency,

wrote Capstone analyst Will Humphrey.

Workforce and Regulatory Challenges

Beyond leadership, the FDA faces workforce issues with significant attrition in key departments. Makary's recent plans to hire additional scientists aim to address this gap, but challenges remain. The agency is also at the brink of several high-profile decisions on treatments for conditions like cancer and ADHD, which could further test its capability and resolve.

As the FDA navigates these turbulent waters, the overarching question remains: will new leadership bring the stability and direction needed, or will the agency continue to be a source of unpredictable policy shifts that unsettle both industries and consumers?